Besides, targeting epigenetic factors such as BRD4 have shown synergistic antitumor effects with PARP inhibitor in a variety of cancer treatment, such combination therapy needs further exploration in the treatment AML (Yang et al., 2017; Sun et al., 2018). Here, PARP1 is linked to acute myeloid leukemia.